Semaglutide vs Tirzepatide
FDA Approved vs FDA Approved
avoid Researched · 95% Both are incretin mimetics with overlapping mechanisms; concurrent use increases side effects.
Molecular Data
Semaglutide Tirzepatide
Weight 4,113.64 Da 4,813.55 Da
Half-life ~7 days (168 hours) ~5 days (120 hours)
Chain 31 amino acids 39 amino acids
Type GLP-1 receptor agonist Dual GLP-1/GIP agonist
Key Benefits
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Tirzepatide
01 Dramatic weight loss (15-22% body weight)
02 Superior diabetes control
03 Reduced cardiovascular risk (26% reduction in MACE)
04 Improved insulin sensitivity
05 Appetite suppression
06 Preserved muscle mass with exercise
Dosing Protocols
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Tirzepatide
2.5mg starting, titrate up to 5-15mg weekly / Once weekly (same day each week)
Weight loss initiation 2.5mg Once weekly x 4 weeks
Weight loss progression 5mg Once weekly
Weight loss optimization 7.5-10mg Once weekly
Maximum weight loss 12.5-15mg Once weekly
Diabetes management (mild) 5-7.5mg Once weekly
Diabetes management (severe) 10-15mg Once weekly
Side Effects
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Tirzepatide
Nausea (mild to moderate, first 2-4 weeks)
Appetite reduction
Possible fatigue during adaptation
Diarrhea or constipation
Reduced food cravings
Contraindications
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Semaglutide Tirzepatide
Status FDA Approved FDA Approved
References 9 studies 8 studies
Latest 2025-06 2025-12
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.